News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F): an All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated


5/30/2013 10:59:29 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HUDDINGE, Sweden & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES